Technical Data
CPI-17 alpha, NT (PKC Potentiated Inhibitor Protein-17)
PKC Potentiated Inhibitor Protein-17 (CPI-17) is a 17kD protein (1). Expressed in smooth muscles and neuronal cells, CPI-17 is a myosin phosphatase inhibitor protein. Phosphorylation of CPI-17 at Thr38 enhances its inhibitory effect by 100 fold (2). Once phosphorylated, CPI-17 inhibits PP1c and MLCP holoenzyme activity (3).

Suitable for use in Western Blot, Immunoprecipitation, Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blotting: 1:1,000-5,000
Immunohistochemistry: 1:250-500
Immunoprecipitation: 1:80

Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot Freeze at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Manufactured incorporating RabMAb® technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.
100ul-20°CBlue IceHumanRabbit
A synthetic peptide corresponding to residues in the N-term of human CPI-17 aplha
Supplied as a liquid
Recognizes human CPI-17 aplha
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Eto, M., et al., FEBS Lett. 410: 356–360, 1997 Eto, M., et al., J. Biol. Chem. 276: 29072–29078, 2001 Eto, M., et al., Neuron 36: 1–20, 2002. Ohki, S., et al., J. Mol. Biol. 314: 839–849, 2001
Eto M, Ohmori T, Suzuki M, Furuya K & Morita F (1995). J Biochem 118, 1104-1107
Eto M, Senba S, Morita F & Yazawa M (1997). FEBS Lett 410, 356-360
Senba S, Eto M & Yazawa M (1999). J Biochem 125, 354-362